Manager TitleAgeSince
President - 29/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
-2.33%+0.53%+51.65%+115.42% 1,031B
-1.06%-1.65%+42.78%+69.98% 638B
-0.65%-1.32%+12.98%+75.49% 462B
-2.66%-1.87%+73.13%+41.15% 359B
-1.20%-5.06%+22.21%+39.08% 335B
-1.52%-0.66%+13.61%+26.57% 273B
-1.83%-2.97%-3.25%+9.88% 253B
-0.50%+3.80%+49.37%+56.84% 228B
-1.47%-1.53%+34.28%+98.89% 185B
Average -0.81%-0.36%+32.97%+59.26% 418.21B
Weighted average by Cap. -1.22%-0.35%+37.38%+71.05%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock